[
    [
        {
            "time": "",
            "original_text": "沃森生物：公司对控股子公司上海泽润在研产品产业化的实施有长远的考虑，目前已经在云南玉溪疫苗产业园建成了HPV疫苗产业化生产车间",
            "features": {
                "keywords": [
                    "沃森生物",
                    "上海泽润",
                    "HPV疫苗",
                    "产业化",
                    "生产车间"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：公司对控股子公司上海泽润在研产品产业化的实施有长远的考虑，目前已经在云南玉溪疫苗产业园建成了HPV疫苗产业化生产车间",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物：公司处于临床研究阶段的各产品的临床试验工作在按计划正常推进",
            "features": {
                "keywords": [
                    "沃森生物",
                    "临床研究",
                    "临床试验",
                    "正常推进"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：公司处于临床研究阶段的各产品的临床试验工作在按计划正常推进",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物：13价肺炎结合疫苗上半年实现销售收入9.89亿元",
            "features": {
                "keywords": [
                    "沃森生物",
                    "13价肺炎结合疫苗",
                    "销售收入",
                    "9.89亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：13价肺炎结合疫苗上半年实现销售收入9.89亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]